This research discusses antibody and non-antibody circulating factors in primary podocytopathies, suggesting therapeutic avenues.
Key Points
Antibody pathogenesis is supported by the presence of anti-nephrin antibodies in many patients with primary podocytopathies.
Significant circulating factors like cardiotrophin-like cytokine 1 are implicated in diseases such as minimal change disease and focal segmental glomerulosclerosis.
The use of immunosuppressive agents, like rituximab, has shown effectiveness in treating podocytopathies, further highlighting antibody involvement.
High-resolution microscopy reveals immunoglobulin deposits that may aid in identifying the underlying mechanisms and potential treatments.